Anavex life sciences reports publication of anavex®3-71 in clinical journal confirming pharmacokinetic dose proportionality of anavex®3-71 in humans

New york, jan. 24, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced a peer-reviewed publication in clinical pharmacology in drug development, findings from the anavex®3-71 first-in-human study which achieved its safety objectives. the publication is entitled, ‘population-based characterization of the pharmacokinetics and food effect of anavex3-71, a novel sigma-1 receptor and allosteric m1 muscarinic receptor agonist in development for treatment of frontotemporal dementia, schizophrenia, and alzheimer disease'.1 the publication reports the population-based characterization of the pharmacokinetics (pk) and food effect of anavex®3-71 as part of the single ascending dose study in healthy participants with the primary objective of assessing dose proportionality of anavex®3-71, and to characterize the effect of food on the pk of anavex®3-71.
AVXL Ratings Summary
AVXL Quant Ranking